BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note published on Thursday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Stock Down 3.3 %

Shares of BIOL stock opened at $0.01 on Thursday. BIOLASE has a 12-month low of $0.02 and a 12-month high of $1.94. The company has a market capitalization of $290,640.90, a PE ratio of 0.00 and a beta of 0.67. The firm has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.03.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.